Animalcare Group
- Company typePublic
- Founded1988
- HeadquartersYork, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Animalcare Group does
Animalcare Group plc is a UK-based international veterinary pharmaceutical and services company listed on the London Stock Exchange's AIM market (ticker ANCR), headquartered in York. The company develops, in-licenses, and commercializes animal health products — primarily pharmaceuticals for companion animals (dogs, cats, horses) — sold through veterinary practices and animal health professionals. Its product portfolio includes established brands such as Daxocox (pain management), the recently acquired Randlab equine-focused range, and an innovation pipeline that includes a VHH antibody R&D collaboration with Orthros Medical (Eurostars-supported), initially targeting canine osteoarthritis and now extended to horses, plus five additional in-house R&D projects.
The company operates a sales-led, distribution-intensive business model: it runs direct commercial operations in seven European countries and exports to more than 40 markets in Europe and beyond, supported by dedicated Senior Executive Team resources for business development, in-licensing, and M&A. Revenue is generated through one-time sales of pharmaceutical products, with a deliberate focus on a smaller number of higher-margin brands, and the Equine segment has expanded materially — from 10% of group revenues in 2024 to approximately 24% in 2025, partly through the start-of-2025 Randlab acquisition. The company is currently in the process of being acquired by Charterhouse Capital Partners for £235.2 million at 336p per share, a transaction approved by shareholders in June 2026 with Australian FIRB clearance secured, and is expected to delist from AIM and re-register as a private company upon court sanction.
Animalcare Group firmographics
Firmographics- Name
- Animalcare Group
- Legal name
- Animalcare Group plc
- Website
- https://animalcaregroup.co.uk
- Company type
- Public
- Founded year
- 1988
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Animalcare Group industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Veterinary Services (54194)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)
- akta.pro secondary industry
- Equine Therapeutics (Rx) (HLAMAEAC)
Keywords
Where Animalcare Group is headquartered
LocationHeadquarters
- HQ city
- York
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Animalcare Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Revenue generated from selling veterinary pharmaceutical products including established brands and newly launched products. The company focuses on higher-margin products and has expanded its Equine segment significantly.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Animalcare Group product offering
Product offeringCore offering
Animalcare Group plc develops, markets and sells veterinary pharmaceutical products for companion animals (dogs, cats) and horses, with a focus on a smaller number of bigger-selling, higher-margin brands. Its portfolio includes the in-house pain management product Daxocox and the Randlab equine range acquired in early 2025, complemented by a proprietary R&D pipeline of five key projects and a VHH antibody research collaboration with Orthros Medical. The business sells through direct commercial presence in seven European countries and exports to more than 40 markets.
Product overview
Animalcare Group plc is an international veterinary pharmaceutical and services business operating as a single unified product portfolio. The company develops and commercializes veterinary pharmaceutical brands including Daxocox (pain management), Randlab products (acquired in 2025), and maintains an R&D pipeline focused on VHH antibody research with Orthros Medical. The company exports to more than 40 markets in Europe and beyond, with direct commercial presence in seven European countries. Higher-margin products and the Equine segment (growing to 24% of revenues from 10%) drive the business model alongside strategic investments like the 25% stake in Australia-based InVetro.
Differentiator
Problem solved
Functional benefit
Products and services
- Daxocox Daxocox is Animalcare's in-house veterinary pharmaceutical product for pain management in animals, sold to veterinary practices and professionals. In FY25 it recorded a double-digit increase in uptake within owned operations following targeted sales and marketing investment.
- Randlab Veterinary Product Range Randlab is a portfolio of veterinary pharmaceutical products, focused on the equine segment, acquired by Animalcare at the start of 2025. It is sold to equine veterinary practices and professionals and was a primary driver of FY2025 revenue and EBITDA growth.
Quantifiable outcome
- 20% revenue growth to £89.1m in FY2025
- +3 more outcomes
Companies that use Animalcare Group
Customer profileSegments2 records
Ideal customer profiles2 records
Animalcare Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Animalcare Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Orthros MedicalcoreVHH antibody research collaboration with Orthros Medical progressing well, initially focused on canine osteoarthritis with research scope extended to horses. This is a Eurostars-supported R&D partnership for innovative veterinary therapeutics.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Animalcare Group competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key highlights6 records
Customer concentration
Animalcare Group social profiles
Digital presenceAnimalcare Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Animalcare Group leadership team
Management profileNumber of profiles
Animalcare Group subsidiaries and ownership
Company hierarchySubsidiaries3 records
Animalcare Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Animalcare Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Animalcare Group
What does Animalcare Group do?
Animalcare Group plc develops, markets and sells veterinary pharmaceutical products for companion animals (dogs, cats) and horses, with a focus on a smaller number of bigger-selling, higher-margin brands. Its portfolio includes the in-house pain management product Daxocox and the Randlab equine range acquired in early 2025, complemented by a proprietary R&D pipeline of five key projects and a VHH antibody research collaboration with Orthros Medical. The business sells through direct commercial presence in seven European countries and exports to more than 40 markets.
Is Animalcare Group a public or private company?
Animalcare Group is a public company. It is classified as public and is currently acquired.
When was Animalcare Group founded?
Animalcare Group was founded in 1988. It employs 101 to 250 people.
Where is Animalcare Group based?
Animalcare Group is headquartered in York, United Kingdom, in the Europe region.
How does Animalcare Group make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Animalcare Group have an API?
No public API is recorded for Animalcare Group.
What industry is Animalcare Group in?
Animalcare Group's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAF, Pain Management, Anesthesia & Critical Care Drugs, with a secondary code of HLAMAEAC, Equine Therapeutics (Rx). Its NAICS code is 54194 and its SIC code is 2834.